Altimmune (ALT) EBITDA Margin (2010 - 2025)
Altimmune (ALT) posted quarterly EBITDA Margin of 111126.92% for Q4 2025, up 38619308.0% year-over-year from N/an in Q4 2024, and up 73.36% quarter-over-quarter from 417180.0% in Q3 2025.
Altimmune (ALT) EBITDA Margin (2010 - 2025) Analysis & Trends
Altimmune (ALT) has reported EBITDA Margin for 16 consecutive years, with 111126.92% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin rose 38619308.0% year-over-year to 111126.92%; the TTM figure through Dec 2025 stood at 230460.98% (up 28539902.0% YoY), while the FY2025 annual figure was 230460.98%, up 28539902.0% from the prior year.
- EBITDA Margin rose to 111126.92% in Q4 2025 per ALT's latest filing, from 417180.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 731.92% in Q4 2021 and bottomed at 1237600.0% in Q3 2022.
- Historically, EBITDA Margin has averaged 283564.09% across 5 years, with a median of 183032.21% in 2025.
- Annual changes were most pronounced in 2022 — EBITDA Margin sank 121658481 bps — and 2023, when it soared 123137348 bps.
- Altimmune's EBITDA Margin stood at 731.92% in 2021, then tumbled by 12036 bps to 88823.08% in 2022, then slipped by 2 bps to 90872.97% in 2023, then plunged by 447 bps to 497320.0% in 2024, then surged by 78 bps to 111126.92% in 2025.
- Business Quant data shows ALT's EBITDA Margin at 111126.92% in Q4 2025, 417180.0% in Q3 2025, and 458440.0% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -111,126.92% |
| Sep 30, 2025 | -417,180.00% |
| Jun 30, 2025 | -458,440.00% |
| Mar 31, 2025 | -436,300.00% |
| Dec 31, 2024 | -497,320.00% |
| Sep 30, 2024 | -495,340.00% |
| Jun 30, 2024 | -534,900.00% |
| Mar 31, 2024 | -535,880.00% |
| Dec 31, 2023 | -90,872.97% |
| Sep 30, 2023 | -6,226.52% |
| Jun 30, 2023 | -300,116.67% |
| Mar 31, 2023 | -103,614.29% |
| Dec 31, 2022 | -88,823.08% |
| Sep 30, 2022 | -1,237,600.00% |
| Jun 30, 2022 | -254,937.50% |
| Mar 31, 2022 | -60,934.38% |
| Dec 31, 2021 | -731.92% |
| Sep 30, 2021 | -21,015.19% |
| Jun 30, 2021 | -18,148.91% |
| Mar 31, 2021 | -1,773.39% |